Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 6—June 2011

Research

Use of Antiviral Drugs to Reduce Household Transmission of Pandemic (H1N1) 2009, United Kingdom1

Richard G. PebodyComments to Author , Ross Harris, George Kafatos, Mary Chamberland, Colin Campbell, Jonathan S. Nguyen-Van-Tam, Estelle McLean, Nick Andrews, Peter J. White, Edward Wynne-Evans, Jon Green, Joanna Ellis, Tim Wreghitt, Sam Bracebridge, Chikwe Ihekweazu, Isabel Oliver, Gillian Smith, Colin Hawkins, Roland Salmon, Brian Smyth, Jim McMenamin, Maria Zambon, Nick F. Phin, and John M. Watson
Author affiliations: Author affiliations: Health Protection Agency, London, UK (R.G. Pebody, R. Harris, G. Kafatos, M. Chamberland, C. Campbell, J.S. Nguyen-Van-Tam, E. McLean, N. Andrews, P.J. White, E. Wynne-Evans, J. Green, J. Ellis, T. Wreghitt, S. Bracebridge, C. Ihekweazu, I. Oliver, G. Smith, C. Hawkins, M. Zambon, N. Phin, J.M. Watson); Imperial College, London (P.J. White); Public Health Wales, Cardiff, Wales, UK (R. Salmon); Public Health Agency Northern Ireland, Belfast, Northern Ireland (B. Smyth); Health Protection Scotland, Glasgow, Scotland (J. McMenamin)

Main Article

Table 4

Univariate and multivariate analysis of pandemic (H1N1) 2009 virus infection SAR for virologically confirmed cases of pandemic (H1N1) 2009 virus infection, by gender, age group, and prophylaxis, United Kingdom, 2009*

Variable
No. contacts†
No. secondary
case-patients
Univariate analysis

Multivariate analysis
SAR, % (95% CI)
p value‡
OR (95% CI)
p value
Sex, n = 745
M 364 37 10.2 (7.5–13.7) 1.0, baseline
F
381
25
6.6 (4.0–10.7)
0.08

1.0 (0.5–2.0)
0.96
Age, y
<16 212 40 18.9 (14.2–24.7) 18.2 (3.9–85.5)
16–49 378 20 5.3 (3.1–9.0) 3.5 (0.7–16.2)
>50
171
2
1.2 (0.3–4.7)
<0.001

1.0, baseline
<0.001
Prophylaxis, n = 587
No 143 45 31.5 (24.4–39.5) 1.0, baseline
Yes
444
8
1.8 (0.8–3.9)
<0.001

0.05 (0.02–0.09)
<0.001
Primary case-patient treatment
>48 h 453 48 10.6 (8.1–13.8) 1.0, baseline
<48 h
308
14
4.5 (2.5–8.1)
0.003

0.30 (0.13–0.68)
0.004
Total 761 62 8.1 (6.4–10.3)

*n = 761 except as indicated. Hosmer-Lemeshow goodness-of-fit test for multivariate model, p = 0.751. SAR, secondary attack rate; CI, confidence interval; OR, odds ratio.
†Excludes co-primary cases.
‡Indicates overall p value for differences by group.

Main Article

1Elements of this work were presented at the Health Protection Agency Annual Conference in 2009. An abstract was presented at the International Conference on Emerging Infectious Diseases, Atlanta, Georgia, USA, 2010.

TOP